BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MAB Discovery Enters Into a Agreement With Top 20 Global Pharma Company


9/27/2012 9:59:25 AM

Munich, Germany, September 27, 2012 / B3C newswire / - MAB Discovery, a provider of exceptional therapeutic monoclonal antibodies, announced today that they have initiated two independent research collaborations with a US oncology focused biotech and a top 20 pharmaceutical company. Employing its unique discovery platform, MAB Discovery will deliver a number of monoclonal antibodies to partner selected targets. Financial terms were not disclosed in either case.

MAB Discovery employs natural immunization of wild type animals (rabbits and rats), followed by fully automated state of the art single B cell cloning and PCR methods to discover high affinity monoclonals covering extensive epitope space. Large and diverse panels of antibodies are created from B cells isolated at various times post immunization. The power of the MAB Discovery platform resides in the vast number of high quality monoclonals from which to choose candidates with desired specificity and functionality. In the case of rabbits, which have been well recognized over the years as excellent sources of high quality antibodies to virtually any antigen, the derived monoclonals are of extreme high affinity (<1nM), obviating the need for time-consuming affinity maturation campaigns with uncertain outcomes. Applications for the MAB Discovery platform range from discovery of monoclonals to novel and difficult targets (eg, GPCRs, ion channels), to finding agents suitable for ADC strategies, to making "biobetters", etc. "I am very pleased with the speed and efficiency by which our CEO, Dr. Stephan Fischer, and his team have been able to establish and validate the platform and to launch these important collaborations", said Dr. Lee Babiss, Chairman of MAB Discovery and CSO of PPD. "Companies such as MAB Discovery are positioned to take advantage of the increased outsourcing of discovery by large pharmas."

Link to the press release

Tweet this press release (URL will be shortened by Twitter)

About MAB Discovery GmbH

MAB Discovery was founded in Munich, Germany in October 2010 by a number of senior executives from Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. Funded by PPD, MAB Discovery follows a service based business model as a basis for its collaborations. Because of this unique funding situation, MAB Discovery can employ a variety of business and collaboration structures to meet the partners' needs.

For further information, please contact:

Dr. Birgit Zech

Head Business Development

Email: birgit.zech@mabdiscovery.com

Phone: +49 89 990 178-0



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES